Eli Lilly And Company
$1.09T- Market cap
- $1.06T
- Debt
- +$42.50B
- Cash
- −$7.27B
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $1.06T · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: LLY stock price at premium vs VRTX $1.12K current versus $770.83 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRTX's multiple
Implied fair value · at LLY's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
LLY vs PFE
Merck & Co., Inc.
LLY vs MRK
Johnson & Johnson
LLY vs JNJ
AbbVie Inc.
LLY vs ABBV
Amgen Inc.
LLY vs AMGN
Bristol-Myers Squibb Company
LLY vs BMY
Gilead Sciences, Inc.
LLY vs GILD
BIOGEN INC.
LLY vs BIIB
Moderna, Inc.
LLY vs MRNA
Illumina, Inc.
LLY vs ILMN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LLY can sustain 40%+ revenue growth and maintain premium margins for an extended period, then hold or add selectively because the current premium to VRTX is already justified only by very strong execution; otherwise, trim or avoid because VRTX-based valuation implies materially lower value than the current price.
LLY trades at a clear premium to VRTX on both earnings and sales-based valuation, with the model implying 37.8% downside to VRTX-derived price. The stock is also already near the top of its historical band, while VRTX implied range sits well below the current price.
Supporting Metrics